Organigram Dramatically Ups Its Investment Into Biosynthesized Cannabis Products

OrganiGram Holdings (NASDAQ: OGI) is helping to push the boundaries of the cannabis industry. The company announced Monday that it is making a fresh $2.5 million investment into Hyasynth Biologicals, a biotech that uses biosynthesis to manufacture cannabinoids.

Cannabinoids are the substances found in marijuana, notably tetrahydrocannabinol, which gets users high.

The deal is part of an arrangement the two companies have, under which OrganiGram may provide three tranches of investment to the privately held Hyasynth. This is the second of the trio; the first was a $5 million round closed in September 2018.

Source Fool.com